Publications by authors named "Wendy Garvin Mayo"
Article Synopsis
- High-risk multiple myeloma (MM) patients, especially those who relapse early after therapy, benefit significantly from the combination of daratumumab with either bortezomib/dexamethasone or lenalidomide/dexamethasone.
- In the CASTOR and POLLUX studies, daratumumab significantly improved progression-free survival (PFS) and overall survival (OS) for relapsed/refractory MM patients across both early and late relapse groups.
- Despite not fully overcoming the risks associated with early relapse, the findings support using daratumumab for patients with one prior line of therapy, enhancing complete response rates and minimal residual disease negativity.
Purpose: With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the time of final analysis for overall survival (OS).
View Article and Find Full Text PDFPurpose: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS).
View Article and Find Full Text PDF